Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemotherapy for Resectable Stage II-III NSCLC
NCT04158440Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2020
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04158440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158440.